AstraZeneca PLC or Biogen Inc.: Who Leads in Yearly Revenue?

AstraZeneca vs. Biogen: A Decade of Revenue Dynamics

In the competitive landscape of the pharmaceutical industry, AstraZeneca PLC and Biogen Inc. have been key players. Over the past decade, AstraZeneca has consistently outperformed Biogen in terms of annual revenue. From 2014 to 2023, AstraZeneca's revenue surged by approximately 75%, peaking at $45.8 billion in 2023. In contrast, Biogen's revenue saw a modest increase of about 1%, reaching $9.8 billion in the same year.

AstraZeneca's growth trajectory is particularly notable from 2020 onwards, with a significant 67% increase in revenue over three years. This period coincides with the company's strategic expansion into oncology and respiratory therapies. Meanwhile, Biogen's revenue has remained relatively stable, reflecting its focus on neurology and rare diseases.

This data highlights AstraZeneca's strategic agility and market adaptability, positioning it as a leader in the pharmaceutical sector.